Search
European Hematology Association tentatively responds to the European Commission’s proposal to improve clinical research
In addition, the regulation appears to accommodate multi-national trials with, for instance, a harmonized authorization dossier, and a single submission system.
Read moreFaculty Information
We are honored that you have agreed to be part of the faculty for the EHA-ISHBT Hematology Tutorial, to be held on March 1-3, 2024 in Hyderabad, India.
Read moreRolling out CAR T across Europe
Prof Christine Chomienne talking about CAR T implementation challenges during the 7th EAPM Presidency Conference in Brussels.
Read moreTarget audience
You are a hematologist working at an academic center or a large community hospital that is known for running clinical trials.
Read moreSGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates among Older Patients with AML
Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.
Read moreThe root of evil: pre-leukemic clones that survive chemotherapy are linked to a higher risk of leukemia recurrence
Acute myeloid leukemia (AML) is an aggressive form of blood cancer. Treatment with intensive chemotherapy often leads to a period of freedom from overt disease called a remission. However, recurrence of the disease is common.
Read moreEvaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Evaluation of 243 patients with deletion 17p chronic lymphocytic leukemia treated with ibrutinib: a cross-study analysis of treatment outcomes
Chronic lymphocytic leukemia (CLL) with the deletion of chromosome 17p (del17p) has been linked to aggressive disease and patient survival of only…